IP Library Granted Patent US 11,497,713
Granted Patent B2
US 11,497,713 · App. 16/225,629 · Granted Nov 15, 2022

Combination taxoid nanoemulsion with immunotherapy in cancer

Inventors: James E. Egan (Massapequa Park, NY); Mansoor Amiji (Attleboro, MA); Iwao Ojima (Port Jefferson, NY)
Assignees: TargaGenix, Inc.; The Research Foundation for The State University of New York; Northeastern University
A61K9/1075A61K31/337A61K39/39558A61K47/44A61K47/542A61P35/00C07K16/2827A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,497,713
App. No.
16/225,629
Granted
Nov 15, 2022
Kind
B2
Abstract

A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.

Claims (11)

1. A method of treating cancer, including the steps of:

administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent which is an anti-PD-L1 antibody to a subject in need of treatment, wherein oil of the NE comprises one or more omega fatty acids; and

treating cancer.

2. The method of claim 1 , wherein the cancer is highly drug resistant.

3. The method of claim 1 , wherein the cancer is chosen from the group consisting of breast, ovary, lung, head and neck, colon, rectal, pancreatic, melanoma, brain, prostate, leukemia, sarcomas, thyroid, Non-Hodgkin Lymphoma, bladder, gliomas, endometrial, and renal cancer.

4. The method of claim 1 , wherein the PUFA is chosen from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and alpha-linolenic acid (LNA).

5. The method of claim 1 , wherein the PUFA-taxoid conjugate is NE-DHA-SBT-1214.

6. The method of claim 1 , wherein the taxoid is chosen from the group consisting of paclitaxel, docetaxel, cabazitaxel, SBT-1213, SBT-12854, SBT-121303; SBT-1216, SBT-11033, SBT-121313, SBT-121602, cabazitaxel, SBT-1212, SBT-1217, SBT-1102, SBT-1103, SBT-1104, SBT-1106, SBT-1107, SBT-121301, SBT-121302, SBT-121304, SBT-121403, SBT-11031, SBT-11032, SBT-11034, SBT-12851, SBT-12852, SBT-12853, SBT-12855, SBT-12851-1, SBT-12851-3, SBT-12852-1, SBT-12852-3, SBT-12853-1, SBT-12853-3, SBT-12854-1, SBT-12854-3, SBT-12855-1, and SBT-12855-3.

7. The method of claim 1 , wherein the oil-in-water NE includes omega-3 fatty acid-rich edible oil.

8. The method of claim 7 , wherein the omega-3 fatty acid-rich edible oil is chosen from the group consisting of fish oil, flax-seed oil, pine nut oil, safflower oil, primrose oil, black currant oil, borage oil, wheat germ oil, chia oil, hemp oil, perilla oil, grape oil, squalene oil, and fungal oil.

9. The method of claim 7 , wherein the omega-3 fatty acid-rich edible oil is modified with a compound chosen from the group consisting of surfactants and targeting agents.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2019
From: EGAN, JAMES E; AMIJI, MANSOOR; OJIMA, IWAO
To: TARGAGENIX, INC.; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK; NORTHEASTERN UNIVERSITY
Reel/Frame 048522/0940 →
Continuity (2)
Provisional Application 62608015 · Dec 20, 2017
Related Publication 20190183796A1 · Jun 20, 2019
Cited By (1)
US 12,186,428